Disease measurable / evaluable within 28 days before the first administration of study treatment
Negative viral serology (HIV 1/2, Ag p24 , HTLV 1/2 , hepatitis B and C, syphilis)
Results of analysis:
* Hemoglobin ≥ 10 g / dl or ≥ 6.25 mmol / l
* Leukocytes ≥ 4000/μl
* Lymphocytes ≥ 1500/μl
* Platelets ≥ 80.000/μl
* Creatinine ≤ 2.5 N
* Total bilirubin ≤ 3 N
* AST and ALT ≤ 3 N without liver metastases; ≤ 5 N with liver metastases
Negative pregnancy test for women of childbearing age
Patient affiliated to a social security system
Patient who has signed informed consent
You may not be if
Brain metastases
Ocular primitive melanoma
Treatment of metastatic melanoma by more than two lines (chemotherapy , immunotherapy, targeted therapy or radiotherapy) or within 4 weeks before the inclusion
Treatment with ipilimumab within 8 weeks before the inclusion
Known allergy to albumin
Contraindication to the use of vasopressors
Positive viral serology for HIV 1/2 , Ag p24 , HTLV 1/2, hepatitis B or C, or syphilis
Women who are pregnant, nursing or refusing to use contraceptives, women with no negative pregnancy test at baseline
Presence of a second active cancer (with the exception of cervical cancer in situ or skin cancer other than melanoma)
History of event or current event of a progressive or non-stabilized severe heart disease (congestive heart failure, coronary artery disease, uncontrolled hypertension, serious arrhythmias or ECG signs of previous myocardial infarction)
Uncontrolled thyroid dysfunction
Any serious acute or chronic illness (active infection requiring antibiotics, bleeding disorders or other condition requiring concomitant treatment not allowed in this study)
History of chronic autoimmune disease (Addison's disease, multiple sclerosis, Graves' disease, rheumatoid arthritis, systemic lupus erythematosus, ... ) with the exception of patients with active vitiligo or a history of vitiligo
History of uveitis and retinopathy associated with melanoma
Adults under a legal protection regime (guardianship, trusteeship, "sauvegarde de justice")
Clareo Health | Adoptive Transfer of Specific Melanoma Antigens CD8+ T Cells in Metastatic Melanoma Patients: a Phase I/II Study
